{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The distribution of time to progression will be estimated using the method of Kaplan-Meier.","groups":[{"description":"Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Enzyme Inhibitor Therapy)"}],"populationDescription":"No participants proceeded to Phase II for evaluation.","reportingStatus":"POSTED","timeFrame":"Time from registration to the time of progression","title":"Time to Progression (Phase II)","type":"SECONDARY"}